The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association of T- and B-cell receptor repertoires with molecular subtypes and outcome in HER2+ breast cancer: An analysis of the NeoALTTO clinical trial.
 
Mattia Rediti
No Relationships to Disclose
 
David Venet
No Relationships to Disclose
 
Francoise Rothe
No Relationships to Disclose
 
Tao Qing
No Relationships to Disclose
 
Marion Maetens
No Relationships to Disclose
 
Ian Bradbury
No Relationships to Disclose
 
Miguel A. Izquierdo
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Serena Di Cosimo
No Relationships to Disclose
 
Florentine Hilbers
Research Funding - Genentech/Roche (Inst); Novartis (Inst); Pfizer (Inst)
 
Mohammed Bajji
Research Funding - Novartis (Inst)
 
Nadia Harbeck
Stock and Other Ownership Interests - West German Study Group
Honoraria - Amgen; AstraZeneca; Genomic Health; Novartis; Pfizer; Pierre Fabre; Roche; Zodiac Pharma
Consulting or Advisory Role - Agendia; AstraZeneca; Celgene; Daiichi Sankyo; Lilly; Merck Sharp & Dohme; Novartis; Odonate Therapeutics; Pfizer; Pierre Fabre; Roche/Genentech; Sandoz; Seagen; West German Study Group (I)
Research Funding - Lilly (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
 
Michael Untch
Honoraria - Art tempi (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo (Inst); MSD Oncology (Inst); Mundipharma (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche Pharma AG (Inst)
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); Celgene (Inst); Lilly (Inst); MSD Oncology (Inst); Mundipharma (Inst); Novartis (Inst); Pfizer (Inst); Roche Pharma AG (Inst)
 
Minetta C. Liu
Research Funding - Eisai (Inst); GRAIL (Inst); Janssen Diagnostics (Inst); Merck (Inst); Novartis (Inst); Roche/Genentech (Inst); Seagen (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - AstraZeneca (Inst); Genomic Health; GRAIL; ION Pharma (Inst); Menarini Silicon Biosystems; Merck; Pfizer
 
Cristina Saura
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Eisai; Genomic Health; MSD; Novartis; Pfizer; Philips HealthWorks; Pierre Fabre; Pique; Puma Biotechnology; Roche; Sanofi; Synthon
Research Funding - AstraZeneca (Inst); Genentech (Inst); Macrogenics (Inst); Novartis (Inst); Pfizer (Inst); Pique (Inst); Puma Biotechnology (Inst); Roche (Inst); Synthon (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Genomic Health; Novartis; Pfizer; Puma Biotechnology; Roche
 
Jens Bodo Huober
Honoraria - Abbvie; AstraZeneca; Celgene; Celgene; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Consulting or Advisory Role - Abbvie; AstraZeneca; Celgene; Eisai; Hexal; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Research Funding - Celgene (Inst); Hexal; Novartis (Inst)
Travel, Accommodations, Expenses - Celgene; Daiichi Sankyo; Novartis; Pfizer; Roche
 
Paolo Nuciforo
Honoraria - Bayer; MSD Oncology; MSD Oncology; Novartis
Consulting or Advisory Role - Bayer; MSD Oncology
Travel, Accommodations, Expenses - Novartis
 
Roberto Salgado
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Roche
Research Funding - Merck; Puma Biotechnology
Travel, Accommodations, Expenses - Merck; Roche
 
Sherene Loi
Consulting or Advisory Role - Aduro Biotech (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); G1 Therapeutics (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)
Research Funding - Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); Seagen (Inst)
 
Lajos Pusztai
Consulting or Advisory Role - Almac Diagnostics; AstraZeneca; Athenex; Bristol-Myers Squibb; Clovis Oncology; Eisai; H3 Biomedicine; Immunomedics; Merck; Novartis; Roche/Genentech; Seagen; Syndax
Research Funding - AstraZeneca (Inst); Genentech (Inst); Merck (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca
(OPTIONAL) Uncompensated Relationships - NanoString Technologies
 
Christos Sotiriou
Consulting or Advisory Role - Amgen; Amgen; Astellas Pharma; Astellas Pharma; CEPHEID; Merck; Puma Biotechnology; Seagen; Vertex
Speakers' Bureau - Eisai; Foundation Medicine; Genomic Health; Prime Oncology; Teva
Patents, Royalties, Other Intellectual Property - A companion diagnostic for CDK4/CDK6 inhibitory drugs based on CDK4 Phosphorylation. Which patient to be treated and how. PCT/EP2017/061780; Epigenetic portraits of human Breast Cancer, PCT/EP2012/050836, WO2012/098215
Travel, Accommodations, Expenses - Roche; Roche/Genentech; Roche/Genentech